As fertility rates fall, private equity is turning fertility care into a fast growing healthcare roll up.
Fertility rates are falling across much of the developed world. Yet one corner of reproductive healthcare is expanding rapidly.
Private equity firms have spent the last decade buying up fertility clinics, and they are not slowing down. A shrinking population should mean fewer patients and fewer dollars, but that is not how the fertility business works. As parenthood gets pushed later into people’s thirties and forties, a larger share of people who want children need medical help to have them. Fewer total births can still produce more spending per intended birth. That gap is where the money is.
A shrinking pool, a growing bill
Delay is the engine. People are marrying later and building careers before trying for children, often for reasons that have little to do with biology itself, from housing costs to unstable job markets. But fertility declines steadily after the early thirties and drops sharply after forty, and the later people wait, the more of them will need assistance they would not have needed a decade earlier.
The federal government tracks exactly how large that population has become. In 2022, American fertility clinics performed 435,426 assisted reproductive technology cycles on 251,542 patients, according to the CDC. Those cycles resulted in 94,039 live-birth deliveries and 98,289 live-born infants, about 2.6 percent of all infants born in the country that year. More than 184,000 of those cycles were egg or embryo freezing cycles, where nothing was transferred, only frozen for later. A substantial share of the industry’s activity, in other words, is not about treating infertility in the moment. It is about banking reproductive capacity against the future.
None of it is cheap. The American Society for Reproductive Medicine puts the cost of a single IVF cycle at roughly fifteen to twenty five thousand dollars, and many patients require more than one cycle to achieve a live birth. This is exactly the kind of patient population private capital has learned to love elsewhere in healthcare: motivated, often facing substantial out of pocket costs, and willing to spend heavily because the alternative is not having a child at all.
Why private equity chose fertility
Fertility is only the latest sector to get the roll up treatment. The same strategy has already reshaped dentistry, dermatology, veterinary medicine and eye care, and the underlying logic is always the same. Buy a handful of small, independent practices, combine their back offices, centralize purchasing and lab work, install shared management, then buy more and repeat. Each acquisition alone is modest. Stitched together into a national platform, the whole is worth substantially more than what the individual pieces were worth on their own, because larger platforms typically sell for a much richer multiple of earnings than the small practices used to build them. That difference between the buying price and the selling price is one of the central economic products private equity is manufacturing in a roll up like this.
The rest of the model is built around a specific kind of patient relationship. A fertility patient does not usually walk in, pay once and leave. She may return for a second cycle, come back for genetic testing, and pay an annual fee to keep eggs or embryos frozen. A platform that owns the clinic and controls more of the surrounding laboratory, testing and administrative infrastructure can capture value at more points along that journey, instead of at just the initial procedure. Combine that with prices high enough to matter, a patient base that is substantially paying cash rather than relying on insurance, and centralized infrastructure that gets cheaper per patient as the platform grows, and the full picture of the investment thesis comes into view: high value procedures, repeat relationships, and consolidation, aimed at an eventual sale of the whole platform at a richer valuation than any of its individual pieces could command alone.
Fertility fit that playbook closely. The sector was highly fragmented, with many clinics operating as small, physician owned practices with limited scale and no real leverage over lab costs or drug pricing, and that fragmentation is precisely what makes a sector attractive to a roll up buyer. A platform that owns dozens of clinics can centralize embryology labs, negotiate bulk pricing on fertility medications, standardize protocols across locations and build a single recognizable consumer brand, in a way no individual clinic ever could. It becomes clear why fertility looked, to a buyout firm, less like medicine and more like an underpriced business.
Because most states restrict who can legally own a medical practice, these deals are typically structured through management services organizations. The clinic keeps its medical license and its doctors. Depending on the structure, the investor backed MSO may own or control the laboratory infrastructure, real estate, administrative operations and brand, and charges a management fee in return. This is a long standing legal structure used across physician heavy specialties to separate clinical ownership from nonclinical operations, and fertility has adopted it widely. It has not gone unnoticed by regulators. Two California laws signed in October 2025, SB 351 and AB 1415, specifically restrict how much influence investor backed management companies can exert over clinical decisions, part of a broader wave of state level oversight that is beginning to catch up with a structure that expanded faster than oversight in some states.
The scale of the shift is no longer subtle. A study published in JAMA in December 2025 found that the share of United States fertility clinics affiliated with a private equity or venture capital firm rose from under 4 percent in 2013 to 32.1 percent by the end of 2023. That smaller group of clinics, roughly a third of the total, was estimated to be performing around 54 percent of all IVF cycles nationwide, based on the most recent full year of cycle data available at the time. In more than a dozen states, private equity affiliated clinics accounted for the overwhelming majority, in some cases nearly all, of the cycles performed. A financial buyer does not need to own most of an industry to capture most of its volume. It only needs to own the busiest clinics, and fertility rolled up faster than almost anyone outside the industry noticed.
Capital does have a legitimate case to make here. Centralized laboratories, shared genetic testing infrastructure and standardized protocols can be expensive to build, and a well capitalized platform is often better positioned to fund them than a single doctor working out of a small practice. Investors also point to expanded geographic access, since a platform with capital to open new locations can bring care to regions a lone practitioner never could afford to serve. Whether that investment ultimately benefits patients more than it benefits the investors who fund it is the real question hanging over the sector, not whether outside capital belongs in medicine at all.
Egg freezing and the employer funnel
IVF itself is largely an acute service. A patient needs it, uses it, and in most cases moves on, which caps how much revenue a single patient can generate. Egg freezing changes that. A woman who freezes her eggs in her early thirties may become a long term storage customer for years, sometimes a decade or more, paying an annual fee that behaves less like a one time medical charge and more like a subscription that renews itself until she either uses the eggs, lets them go, or decides she no longer wants them. In the United Kingdom, where the regulator publishes detailed figures, annual egg freezing cycles rose from 2,567 in 2019 to 6,932 in 2023, a scale of growth that shows how quickly this category has moved from medical footnote to mainstream service line.
It is not a guarantee of a future child. It is the sale of an option on one, and optionality is a far easier thing to market to a career focused thirty year old than a diagnosis of infertility.
Employers have become an important channel through which patients reach these clinics in the first place, but they are not the only one. Patients increasingly find clinics on their own too, comparing options online and following fertility content on social media before ever booking an appointment, a shift the UK regulator has explicitly noted as patients behaving more like consumers shopping for a service. Fertility benefits have expanded beyond a niche perk at a handful of tech companies into a broader employer benefit, used to recruit and retain highly educated employees who are delaying parenthood to build careers. Much of that spending runs through a layer of venture backed benefit administrators, companies such as Progyny and Carrot, that contract with large employers and then direct their covered employees into specific networks of fertility providers. A related company, Kindbody, occupies a somewhat different position in the market, since it operates its own clinics in addition to selling employer benefits, making it both a distribution channel and a clinic operator at once. For a clinic on the receiving end of these referrals, the arrangement can supply a steady stream of covered patients without the clinic having to acquire each one directly through its own advertising.
Around that core relationship sits a market for additional procedures and technologies, from preimplantation genetic testing and ICSI to assisted hatching and newer AI based embryo assessment tools. These are not all the same kind of thing. ICSI and genetic testing are established techniques with specific clinical indications for particular patients. Others are offered more broadly as optional upgrades with a thinner evidence base behind them. The UK’s fertility regulator, which maintains a public ratings system for treatment add-ons specifically, has said that most of them have not been shown through good quality evidence to improve a typical patient’s chance of having a baby. Not everything marketed as an upgrade has earned that status through evidence, and it is worth patients asking, procedure by procedure, which category a given add-on actually falls into.
Outcomes are also harder to evaluate than the marketing around them suggests. Fertility treatment does not sell a guaranteed result. It sells a chance, often a repeated chance, at a result that may or may not happen. The CDC itself warns that average clinic success rates vary substantially by a patient’s age, diagnosis and treatment history, and that published averages may not reflect an individual’s actual odds. Two clinics can publish very different headline numbers while treating very different patient populations, which makes clinic comparison shopping a far less reliable exercise than the marketing around it often implies, and it is exactly the kind of asymmetry a consolidating, brand driven industry is well positioned to exploit.
The capacity money cannot buy
There is a limit to how fast this business can scale, and it has little to do with capital. Money can buy clinics, equipment and buildings quickly. Fertility care depends on a specialized workforce that cannot be expanded nearly as fast as capital can be deployed, from reproductive endocrinologists to embryologists to the genetic counselors and lab technicians who run the embryology suite day to day. Reproductive endocrinology in particular is a narrow subspecialty with a training pipeline that produces only a small number of new physicians each year, and that pipeline does not expand simply because a platform has raised more capital.
Specialists hold real leverage as a result. Platforms can respond with equity stakes, retention agreements and other incentives designed to keep founding doctors and senior embryologists in place after an acquisition. Some are also extending nurse practitioners and physician assistants further into patient management, and exploring AI tools aimed at parts of the embryology workflow that do not strictly require a physician’s judgment. Whether that meaningfully expands the effective supply of care, or simply shifts more of the workload downward while the underlying shortage of specialists remains the industry’s hard ceiling, is not yet settled.
The pressure this creates on individual physicians is not abstract. Peter McGovern, a reproductive endocrinologist and associate REI fellowship director at Rutgers New Jersey Medical School, has written that offers to buy his practice now arrive on a near weekly basis, often for sums large enough to make accepting genuinely tempting, and has urged colleagues to think carefully before trading clinical independence for a payout. That tension, between an offer real enough to reshape a career and a shortage severe enough to make each individual doctor hard to replace, is what gives specialists their leverage in the first place.
Where regulation is catching up
Fertility medicine occupies an unusual position in most countries, treated more like elective, market driven healthcare than the rest of medicine, and consolidation has moved faster than the rules meant to govern it.
In the United Kingdom, the fertility regulator has openly said the sector has become significantly more commercial, with a growing share of clinics belonging to larger corporate groups, and that its framework has struggled to keep pace with online services and changing treatment models. In India, growing concern over irregularities at fertility clinics led the National Commission for Women to form a high level expert committee in July 2026 to review the laws governing IVF clinics, assisted reproductive technology centers and gamete banks, with a specific mandate to examine how well existing safeguards protect the women going through treatment. That committee follows years of uneven enforcement: India’s Assisted Reproductive Technology Act took effect in January 2022, but as of May 2023 only about 5 percent of clinic applications nationwide, 219 of 4,446, had actually been approved under the national registry the law created. In the United States, a separate legal question has emerged that no one fully anticipated: what a frozen embryo actually is under the law. When Alabama’s Supreme Court ruled that frozen embryos could be treated as children under the state’s wrongful death statute, it sent a jolt through an industry that stores millions of embryos in centralized cryobanks. For investors, that creates another category of risk to price alongside medical and reimbursement risk: the legal status of embryos themselves.
A growing number of US states now require insurers to cover IVF, which is generally good for patients, though it also narrows the cash pay margins that made fertility attractive to investors in the first place. Whether that pushes clinics toward add on services insurance does not cover is a reasonable hypothesis, but not one that has been demonstrated with hard data.
The money is going global
Capital keeps moving to wherever demand, pricing power and permissive regulation line up, and this story is no longer confined to the United States. In June 2026, Fakih IVF, one of the largest fertility operators in the Gulf, drew serious interest from a field of bidders that included LetterOne Holdings, Brookfield Asset Management, TA Associates and the Indian maternity chain Cloudnine Group of Hospitals, in a deal Bloomberg reported could rank among the largest healthcare transactions the Middle East has seen. In India, KKR backed IVI RMA is in advanced talks to acquire ART Fertility Clinics in a deal reported at roughly 450 million dollars.
That regional reach goes beyond single, marquee deals. KKR built its European anchor position by paying roughly 3.2 billion dollars for Spain headquartered IVI RMA Global, then added Barcelona based Eugin Group, which operates 69 clinics across 11 countries, in a deal reported at roughly 534 million dollars. Recharge Capital, a New York and Singapore based investment firm, has gone further still, raising a 200 million dollar vehicle explicitly built to roll up fertility and women’s health providers across Southeast Asia, Latin America, Europe and the Middle East at once. Patients are following similar incentives from the other direction, traveling across borders for lower prices, shorter waits or more permissive rules on donor eggs and genetic testing.
The paradox that will not resolve itself
Governments look at falling birth rates and see a demographic emergency: aging populations, shrinking workforces, pension systems running out of contributors. Investors look at the same trend and see a demographic opportunity: delayed parenthood driving more people toward paid treatment, fertility preservation creating recurring revenue, a population willing to pay heavily for the child they postponed having.
Both readings are correct, and that is precisely the problem. Assisted reproduction can help an individual patient have a child she otherwise could not. It cannot address the broader economic and social forces, housing costs, career pressure, shifting attitudes toward family, that are leading entire societies to have fewer children in the first place. One is a problem medicine can treat. The other is not, no matter how much capital gets pointed at it.
That leaves an uncomfortable question sitting at the center of the whole industry. If governments increasingly decide they need more children, does fertility eventually become a public good, something governments fund the way they do basic healthcare or education? Or does it keep evolving the way it has for the last decade, into one of the fastest consolidating private markets in all of healthcare, available in full to whoever can afford the bill? Right now, capital has already answered that question for itself. Everyone else is still deciding.
